Eisai

Companies Eisai

News Eisai

• Eisai: Halaven Receives Approval in Japan for the Treatment of Inoperable and Recurrent Breast Cancer

  Eisai Co., Ltd. announced that it has received approval to market its anticancer Halaven(R) Injection 1mg (eribulin mesylate) in Japan for the treatment of inoperable and recurrent breast cancer. Discovered and developed by Eisai, Halaven is now approved in each of the world's three largest pharmace more

• Eisai's Halaven Receives CHMP Positive Opinion for use in Metastatic Breast Cancer

  The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), gave a positive opinion for the use of Eisai Europe, Ltd.'s Halaven as a monotherapy indicated in the treatment of patients with locally advanced (LA) or metastatic breast more

• Eisai Announces Positive Phase III Trial Results for Perampanel in Partial Epilepsy

  Eisai announced the results of a Phase III study for the investigational compound perampanel (E2007), a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered by Eisai and under development for adjunctive treatment of partial seizures in patients with ep more

Publications Eisai

• Development of perampanel in epilepsy

  Alpha‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid (AMPA)‐type glutamate receptors play a key role in mediating glutamatergic transmission in the cortex. Perampanel (2‐[2‐oxo‐1‐phenyl‐5‐pyridin‐2‐yl‐1,2‐dihydropyridin‐3‐yl] benzonitrile) is a potent, orally active, highly selective, non‐comp more

• Perampanel: newly approved, novel antiepileptic medication for partial-onset seizures

  Evaluation of: French JA, Krauss GL, Steinhoff BJ et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of randomized global Phase III study 305. Epilepsia doi:10.1111/j.1528-1167.2012.03638.x (2012) (Epub ahead of print). Epilepsy is characterized by more

• An in vivo role of Mrp2 in the rat hepatocytes by immunocytochemistry for amoxicillin using the transporter-deficient EHBR

  An in vivo role of the multidrug resistant-associated protein (Mrp2) in rat hepatocytes was examined by immunocytochemistry (ICC) for amoxicillin (AMPC) by the use of the transporter-deficient Eisai hyperbilirubinemic rats (EHBR). The ICC revealed that in the liver of EHBR at 3-h post-administration more

Market studies Eisai

• Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Chemotherapy induced more

• Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020”. The report is an essential source of information and analysis on the global ovarian cancer therapeutics market. The report provi more

• Global Central Nervous System Drugs Market 2011-2015

  TechNavio's analysts forecast the Global Central Nervous System Drugs market to grow at a CAGR of -3.2 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increasing size of aging population. The Global EEG/EMG Equipment market has also been witnessing more

Websites Eisai